IBDEI1XG.m

IBDEI1XG ; ; 04-FEB-2020

 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020

 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y

Q Q

 ;;^UTILITY(U,$J,358.3,30786,1,3,0)

 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney

 ;;^UTILITY(U,$J,358.3,30786,1,4,0)

 ;;=4^I13.0

 ;;^UTILITY(U,$J,358.3,30786,2)

 ;;=^5007067

 ;;^UTILITY(U,$J,358.3,30787,0)

 ;;=I13.10^^123^1587^9

 ;;^UTILITY(U,$J,358.3,30787,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30787,1,3,0)

 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney

 ;;^UTILITY(U,$J,358.3,30787,1,4,0)

 ;;=4^I13.10

 ;;^UTILITY(U,$J,358.3,30787,2)

 ;;=^5007068

 ;;^UTILITY(U,$J,358.3,30788,0)

 ;;=I15.1^^123^1587^11

 ;;^UTILITY(U,$J,358.3,30788,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30788,1,3,0)

 ;;=3^Hypertension Secondary to Oth Renal Disorders

 ;;^UTILITY(U,$J,358.3,30788,1,4,0)

 ;;=4^I15.1

 ;;^UTILITY(U,$J,358.3,30788,2)

 ;;=^5007072

 ;;^UTILITY(U,$J,358.3,30789,0)

 ;;=I15.2^^123^1587^10

 ;;^UTILITY(U,$J,358.3,30789,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30789,1,3,0)

 ;;=3^Hypertension Secondary to Endocrine Disorders

 ;;^UTILITY(U,$J,358.3,30789,1,4,0)

 ;;=4^I15.2

 ;;^UTILITY(U,$J,358.3,30789,2)

 ;;=^5007073

 ;;^UTILITY(U,$J,358.3,30790,0)

 ;;=I50.1^^123^1587^16

 ;;^UTILITY(U,$J,358.3,30790,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30790,1,3,0)

 ;;=3^Left Ventricular Failure

 ;;^UTILITY(U,$J,358.3,30790,1,4,0)

 ;;=4^I50.1

 ;;^UTILITY(U,$J,358.3,30790,2)

 ;;=^5007238

 ;;^UTILITY(U,$J,358.3,30791,0)

 ;;=E26.09^^123^1587^17

 ;;^UTILITY(U,$J,358.3,30791,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30791,1,3,0)

 ;;=3^Primary Hyperaldosteronism,Other

 ;;^UTILITY(U,$J,358.3,30791,1,4,0)

 ;;=4^E26.09

 ;;^UTILITY(U,$J,358.3,30791,2)

 ;;=^5002735

 ;;^UTILITY(U,$J,358.3,30792,0)

 ;;=I15.8^^123^1587^18

 ;;^UTILITY(U,$J,358.3,30792,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30792,1,3,0)

 ;;=3^Secondary Hypertension,Other

 ;;^UTILITY(U,$J,358.3,30792,1,4,0)

 ;;=4^I15.8

 ;;^UTILITY(U,$J,358.3,30792,2)

 ;;=^5007074

 ;;^UTILITY(U,$J,358.3,30793,0)

 ;;=E27.5^^123^1587^1

 ;;^UTILITY(U,$J,358.3,30793,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30793,1,3,0)

 ;;=3^Adrenomedullary Hyperfunction

 ;;^UTILITY(U,$J,358.3,30793,1,4,0)

 ;;=4^E27.5

 ;;^UTILITY(U,$J,358.3,30793,2)

 ;;=^5002744

 ;;^UTILITY(U,$J,358.3,30794,0)

 ;;=E26.01^^123^1587^4

 ;;^UTILITY(U,$J,358.3,30794,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30794,1,3,0)

 ;;=3^Conn's Syndrome

 ;;^UTILITY(U,$J,358.3,30794,1,4,0)

 ;;=4^E26.01

 ;;^UTILITY(U,$J,358.3,30794,2)

 ;;=^329905

 ;;^UTILITY(U,$J,358.3,30795,0)

 ;;=I15.9^^123^1587^19

 ;;^UTILITY(U,$J,358.3,30795,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30795,1,3,0)

 ;;=3^Secondary Hypertension,Unspec

 ;;^UTILITY(U,$J,358.3,30795,1,4,0)

 ;;=4^I15.9

 ;;^UTILITY(U,$J,358.3,30795,2)

 ;;=^5007075

 ;;^UTILITY(U,$J,358.3,30796,0)

 ;;=B20.^^123^1588^3

 ;;^UTILITY(U,$J,358.3,30796,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30796,1,3,0)

 ;;=3^HIV Disease

 ;;^UTILITY(U,$J,358.3,30796,1,4,0)

 ;;=4^B20.

 ;;^UTILITY(U,$J,358.3,30796,2)

 ;;=^5000555

 ;;^UTILITY(U,$J,358.3,30797,0)

 ;;=J18.9^^123^1588^6

 ;;^UTILITY(U,$J,358.3,30797,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30797,1,3,0)

 ;;=3^Pneumonia,Unspec Organism

 ;;^UTILITY(U,$J,358.3,30797,1,4,0)

 ;;=4^J18.9

 ;;^UTILITY(U,$J,358.3,30797,2)

 ;;=^95632

 ;;^UTILITY(U,$J,358.3,30798,0)

 ;;=J10.1^^123^1588^1

 ;;^UTILITY(U,$J,358.3,30798,1,0)

 ;;=^358.31IA^4^2

 ;;^UTILITY(U,$J,358.3,30798,1,3,0)

 ;;=3^Flu w/ Respiratory Manifestations

--- Routine Detail   --- with STRUCTURED ROUTINE LISTING ---IBDEI1XG   3753     printed  Feb 18, 2025@23:44:02                                                                                                                                                                                                    Page 2

IBDEI1XG  ; ; 04-FEB-2020

 +1       ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020

 +2        if 'DIFQR(358.3)

               QUIT 

           FOR I=1:2

               SET X=$TEXT(Q+I)

               if X=""

                   QUIT 

               SET Y=$EXTRACT($TEXT(Q+I+1),4,999)

               SET X=$EXTRACT(X,4,999)

               if $ASCII(Y)=126

                   SET I=I+1

                   SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)

               if $ASCII(Y)=61

                   SET Y=$EXTRACT(Y,2,999)

               XECUTE NO

              IF '$TEST

                   SET @X=Y

Q          QUIT 

 +1       ;;^UTILITY(U,$J,358.3,30786,1,3,0)

 +2       ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 1-4 Chr Kidney

 +3       ;;^UTILITY(U,$J,358.3,30786,1,4,0)

 +4       ;;=4^I13.0

 +5       ;;^UTILITY(U,$J,358.3,30786,2)

 +6       ;;=^5007067

 +7       ;;^UTILITY(U,$J,358.3,30787,0)

 +8       ;;=I13.10^^123^1587^9

 +9       ;;^UTILITY(U,$J,358.3,30787,1,0)

 +10      ;;=^358.31IA^4^2

 +11      ;;^UTILITY(U,$J,358.3,30787,1,3,0)

 +12      ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 1-4 Chr Kidney

 +13      ;;^UTILITY(U,$J,358.3,30787,1,4,0)

 +14      ;;=4^I13.10

 +15      ;;^UTILITY(U,$J,358.3,30787,2)

 +16      ;;=^5007068

 +17      ;;^UTILITY(U,$J,358.3,30788,0)

 +18      ;;=I15.1^^123^1587^11

 +19      ;;^UTILITY(U,$J,358.3,30788,1,0)

 +20      ;;=^358.31IA^4^2

 +21      ;;^UTILITY(U,$J,358.3,30788,1,3,0)

 +22      ;;=3^Hypertension Secondary to Oth Renal Disorders

 +23      ;;^UTILITY(U,$J,358.3,30788,1,4,0)

 +24      ;;=4^I15.1

 +25      ;;^UTILITY(U,$J,358.3,30788,2)

 +26      ;;=^5007072

 +27      ;;^UTILITY(U,$J,358.3,30789,0)

 +28      ;;=I15.2^^123^1587^10

 +29      ;;^UTILITY(U,$J,358.3,30789,1,0)

 +30      ;;=^358.31IA^4^2

 +31      ;;^UTILITY(U,$J,358.3,30789,1,3,0)

 +32      ;;=3^Hypertension Secondary to Endocrine Disorders

 +33      ;;^UTILITY(U,$J,358.3,30789,1,4,0)

 +34      ;;=4^I15.2

 +35      ;;^UTILITY(U,$J,358.3,30789,2)

 +36      ;;=^5007073

 +37      ;;^UTILITY(U,$J,358.3,30790,0)

 +38      ;;=I50.1^^123^1587^16

 +39      ;;^UTILITY(U,$J,358.3,30790,1,0)

 +40      ;;=^358.31IA^4^2

 +41      ;;^UTILITY(U,$J,358.3,30790,1,3,0)

 +42      ;;=3^Left Ventricular Failure

 +43      ;;^UTILITY(U,$J,358.3,30790,1,4,0)

 +44      ;;=4^I50.1

 +45      ;;^UTILITY(U,$J,358.3,30790,2)

 +46      ;;=^5007238

 +47      ;;^UTILITY(U,$J,358.3,30791,0)

 +48      ;;=E26.09^^123^1587^17

 +49      ;;^UTILITY(U,$J,358.3,30791,1,0)

 +50      ;;=^358.31IA^4^2

 +51      ;;^UTILITY(U,$J,358.3,30791,1,3,0)

 +52      ;;=3^Primary Hyperaldosteronism,Other

 +53      ;;^UTILITY(U,$J,358.3,30791,1,4,0)

 +54      ;;=4^E26.09

 +55      ;;^UTILITY(U,$J,358.3,30791,2)

 +56      ;;=^5002735

 +57      ;;^UTILITY(U,$J,358.3,30792,0)

 +58      ;;=I15.8^^123^1587^18

 +59      ;;^UTILITY(U,$J,358.3,30792,1,0)

 +60      ;;=^358.31IA^4^2

 +61      ;;^UTILITY(U,$J,358.3,30792,1,3,0)

 +62      ;;=3^Secondary Hypertension,Other

 +63      ;;^UTILITY(U,$J,358.3,30792,1,4,0)

 +64      ;;=4^I15.8

 +65      ;;^UTILITY(U,$J,358.3,30792,2)

 +66      ;;=^5007074

 +67      ;;^UTILITY(U,$J,358.3,30793,0)

 +68      ;;=E27.5^^123^1587^1

 +69      ;;^UTILITY(U,$J,358.3,30793,1,0)

 +70      ;;=^358.31IA^4^2

 +71      ;;^UTILITY(U,$J,358.3,30793,1,3,0)

 +72      ;;=3^Adrenomedullary Hyperfunction

 +73      ;;^UTILITY(U,$J,358.3,30793,1,4,0)

 +74      ;;=4^E27.5

 +75      ;;^UTILITY(U,$J,358.3,30793,2)

 +76      ;;=^5002744

 +77      ;;^UTILITY(U,$J,358.3,30794,0)

 +78      ;;=E26.01^^123^1587^4

 +79      ;;^UTILITY(U,$J,358.3,30794,1,0)

 +80      ;;=^358.31IA^4^2

 +81      ;;^UTILITY(U,$J,358.3,30794,1,3,0)

 +82      ;;=3^Conn's Syndrome

 +83      ;;^UTILITY(U,$J,358.3,30794,1,4,0)

 +84      ;;=4^E26.01

 +85      ;;^UTILITY(U,$J,358.3,30794,2)

 +86      ;;=^329905

 +87      ;;^UTILITY(U,$J,358.3,30795,0)

 +88      ;;=I15.9^^123^1587^19

 +89      ;;^UTILITY(U,$J,358.3,30795,1,0)

 +90      ;;=^358.31IA^4^2

 +91      ;;^UTILITY(U,$J,358.3,30795,1,3,0)

 +92      ;;=3^Secondary Hypertension,Unspec

 +93      ;;^UTILITY(U,$J,358.3,30795,1,4,0)

 +94      ;;=4^I15.9

 +95      ;;^UTILITY(U,$J,358.3,30795,2)

 +96      ;;=^5007075

 +97      ;;^UTILITY(U,$J,358.3,30796,0)

 +98      ;;=B20.^^123^1588^3

 +99      ;;^UTILITY(U,$J,358.3,30796,1,0)

 +100     ;;=^358.31IA^4^2

 +101     ;;^UTILITY(U,$J,358.3,30796,1,3,0)

 +102     ;;=3^HIV Disease

 +103     ;;^UTILITY(U,$J,358.3,30796,1,4,0)

 +104     ;;=4^B20.

 +105     ;;^UTILITY(U,$J,358.3,30796,2)

 +106     ;;=^5000555

 +107     ;;^UTILITY(U,$J,358.3,30797,0)

 +108     ;;=J18.9^^123^1588^6

 +109     ;;^UTILITY(U,$J,358.3,30797,1,0)

 +110     ;;=^358.31IA^4^2

 +111     ;;^UTILITY(U,$J,358.3,30797,1,3,0)

 +112     ;;=3^Pneumonia,Unspec Organism

 +113     ;;^UTILITY(U,$J,358.3,30797,1,4,0)

 +114     ;;=4^J18.9

 +115     ;;^UTILITY(U,$J,358.3,30797,2)

 +116     ;;=^95632

 +117     ;;^UTILITY(U,$J,358.3,30798,0)

 +118     ;;=J10.1^^123^1588^1

 +119     ;;^UTILITY(U,$J,358.3,30798,1,0)

 +120     ;;=^358.31IA^4^2

 +121     ;;^UTILITY(U,$J,358.3,30798,1,3,0)

 +122     ;;=3^Flu w/ Respiratory Manifestations